Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pazopanib in Pediatric and Young Adult Refractory Solid Tumors
2013-003595-12Phase 2
- Sponsor
- GSK
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pazopanib in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), Ewing sarcoma and 4 more, sponsored by GSK. Primary endpoint: Objective response rate in rhabdomyosarcoma, non-rhabdomyosarcomatous soft tissue sarcomas and Ewing sarcoma.
02
Drugs
pazopanib
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)Ewing sarcomaosteosarcoma (OS)neuroblastoma
Beyond the preview
Go deeper on 2013-003595-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003595-12.